Trials / Completed
CompletedNCT03412747
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Phase 3, Multicenter, Randomized, Double-Blind Study With an Active-Controlled Initial Treatment Period Followed by a Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 478 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to compare the efficacy of bimekizumab versus adalimumab in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimekizumab | Subjects will receive bimekizumab at pre-defined timepoints in dose regimen 1 and/or dose regimen 2. |
| DRUG | Adalimumab | Adalimumab will be administered according to the labeling recommendations. |
| OTHER | Placebo | Subjects will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products (IMP). |
Timeline
- Start date
- 2018-01-26
- Primary completion
- 2019-02-07
- Completion
- 2020-02-26
- First posted
- 2018-01-26
- Last updated
- 2026-04-15
- Results posted
- 2022-03-02
Locations
77 sites across 9 countries: United States, Australia, Canada, Germany, Hungary, Poland, Russia, South Korea, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03412747. Inclusion in this directory is not an endorsement.